Tagged with M

Egypt The head of the French Chamber of Commerce in Egypt, Karim Wissa, dives into the current state of the Egyptian economy, the reasons behind its healthcare boom, explains why companies are rushing in under the umbrella of the universal healthcare law, and the role of France in helping Egypt grow.…

Italy Pierre Fabre Italy’s Charles-Henri Bodin highlights how the French firm’s offering has expanded far beyond its dermo-cosmetics heritage to today encompass a wide range of pharmaceuticals, including the key growth area of oncology. Bodin also outlines the importance of Italy – one of PF’s first international affiliates – to the…

Korea Stephen Yoo highlights the pioneering work that STCube Pharmaceuticals – a US subsidiary of Korean firm STCube – is undertaking in the immuno-oncology field, its three technology platforms, partnership approach, and his outlook for the company’s future.   Immuno-oncology has revolutionized cancer therapy, but despite the huge success there has…

Algeria A snapshot of Algeria, one of the key countries driving growth in MENA, a region that accounts for just 2 percent of world’s pharma market but that is estimated to reach around USD 60 billion by 2025. Algeria has steadily improved its essential health care services. Hecho conVisme Infographic Maker…

Turkey After its best financial year to date – posting revenues of USD 27.3 billion in 2021 – Gilead has said yes to localization in Turkey. The California-based company, known for its HIV and oncology treatments, announced a USD 60 million investment in Turkey, partnering with local player Pharmactive to produce…

Korea Founder and CEO of GeneMedicine, Dr Chae-Ok Yun, explains how the company, specialised in oncolytic virus development, has progressed since we last interviewed her two years ago, with one of its candidates getting close to phase II clinical trials and the construction of a new manufacturing facility that will enable…

Global French mid-cap Ipsen has signed an agreement to acquire US-based oncology specialist Epizyme, with its lymphoma drug, Tazverik, for USD 247 million to bolster its growing oncology presence. Ipsen recently announced that the deal with Epizyme’s will focus on Tazverik (tazemetostat), a first-in-class EZH2a inhibitor approved in the U.S. in…

Spain UCB’s general manager for Iberia, Pau Ricós, comments on the Belgian company’s upcoming launches, its focus on immunology and neurology, and the importance of R&D – UCB spent around 28 percent of its revenues on R&D in 2021. In addition, Ricós analyses Spain’s slow access to innovation and the pros…

Europe In Europe, patient access to Orphan Medicinal Products (OMP) for the treatment of rare diseases remains inequitable. With the common goal of ensuring broader and faster access to OMPs across Europe, EURORDIS and EFPIA have joined forces to propose a series of solutions. According to a 2020 study, fragmentation of…

Global David H. Crean, Managing General Partner for Equitos Venture Partners and Cardiff Advisory, highlights news from the recent BIO Convention held face-to-face in San Diego, CA for the first time since the start of the COVID-19 pandemic. After more than two years, the 2022 BIO International Convention (BIO2022) was back…

Brazil The latest from Brazilian Pharma, including the approval of home grown cannabis for medical use, Cellera Farma’s partnership with Ferring, a considerable increase in demand for oncology drugs, and a dire diabetes prediction.   Brazil court approves home grown cannabis for medical use (ABC News) A top court in Brazil…

UAE Taher Shams, Zulekha Healthcare Group’s Managing Director, outlines the group’s expansion in UAE and India and its participation in the Dubai Health Authority’s “Dubai Health Experience” medical tourism portal. In addition, he speaks about fears of market saturation in UAE.  We are the shining star in the Middle East, with…